UK Immunotherapy against Grass Allergies moves on to Phase III Trials

31/05/2016 - 2 minutes

Circassia is beginning a Phase III trial for its short-course immunotherapy for grass allergies. This common type of allergy can significantly impact the life quality of patients.

circassia_allergy_grass_spire_peptide_toleromuneCircassia is based in Oxford (UK) and was part of 2014’s record Biotech IPOs – raising a whopping €268M. It focuses on respiratory diseases, such as asthma and allergies.

Its therapies for allergy are based on synthetic peptide immuno-regulatory epitope class of the therapies (SPIREs).

These first-in-class compounds were designed to induce tolerance to specific allergies with a short course of treatment, by stimulating the formation of allergy-mitigating regulatory T-cells.

Now, Circassia is moving on with the clinical development of one of these treatments. It has initiated a Phase III trial for its grass allergy immunotherapy, designed to meet regulatory requirements for market access in both the US and Europe.

The trial will start by evaluating 400 patients aged 12 to 75 years old. If the results from this group of patients are favourable,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT Do you want to remove this advert? Become a member!
ADVERTISEMENT Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member